← Product Code [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX) · K080643

# ELECSYS ANTI-TSHR CALCHECK (K080643)

_Roche Diagnostics · JJX · Aug 22, 2008 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K080643

## Device Facts

- **Applicant:** Roche Diagnostics
- **Product Code:** [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX.md)
- **Decision Date:** Aug 22, 2008
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1660
- **Device Class:** Class 1
- **Review Panel:** Clinical Chemistry

## Indications for Use

For use in the verification of the calibration established by the Elecsys Anti-TSHR reagent on the indicated Elecsys and cobas e immunoassay analyzers.

## Device Story

Elecsys Anti-TSHR CalCheck is a lyophilized quality control material; consists of human anti-TSHR antibodies in human serum matrix. Used to verify calibration of Elecsys Anti-TSHR reagent on Elecsys and cobas e immunoassay analyzers. Provided at three concentration levels (1 mL each). Reconstituted with distilled/deionized water by laboratory personnel. Value assignment performed using multiple analyzer platforms (Elecsys 2010/cobas e 411 and MODULAR ANALYTICS E170/cobas e 601); target values calculated as median of determined values. Components tested free of HBsAg, HIV, and HCV antibodies.

## Clinical Evidence

No clinical data. Bench testing only. Stability testing protocols and acceptance criteria were found acceptable. Value assignment performed using multiple analyzer platforms.

## Technological Characteristics

Lyophilized human serum matrix containing human anti-TSHR antibodies. Three levels provided. Reconstituted with 1.0 mL distilled/deionized water. Stability: Unopened 2-8°C until expiration; reconstituted 5 hours at 15-25°C. Traceable to NIBSC 1st IS 90/672 standard.

## Regulatory Identification

A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.

## Predicate Devices

- Elecsys C-Peptide CalCheck (k040157)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k080643

B. Purpose for Submission:
Notification of intent to manufacture and market new devices for the verification of calibration of Anti-TSHR on the Elecsys and Cobas e.

C. Measurand:
Control material for Anti-Thyroid-Stimulating Hormone Receptor

D. Type of Test:
Quality Control for the Elecsys Anti-TSHR test system

E. Applicant:
Roche Diagnostics

F. Proprietary and Established Names:
Proprietary – Elecsys Anti-TSHR CalCheck
Established – Quality Control

G. Regulatory Information:
1. Regulation section:
21 CFR 862.1660 Quality control material (assayed and unassayed)
2. Classification:
Class I, reserved
3. Product code:
JJX

{1}

4. Panel:
75

H. Intended Use:

1. Intended use(s):
See Indications for Use below

2. Indication(s) for use:
For use in the verification of calibration established by the Elecsys Anti-TSHR reagent on the indicated Elecsys and cobas e immunoassay analyzers.

3. Special conditions for use statement(s):
For Prescription Use Only

4. Special instrument requirements:
For use on the Elecsys and cobas e immunoassay analyzers.

I. Device Description:
The Elecsys Anti-TSHR CalCheck is a lyophilized product consisting of human anti-TSHR antibodies in human serum matrix. During manufacture, the antibody is spiked into the matrix at the desired concentration levels. The control material is provided at three levels of 1ml each.

All components of the control are tested individually and shown to be free of HBsAG and antibodies to HCV and HIV. The testing methods used were FDA approved or cleared with the European Directive 98/79/EC Annex II List A.

J. Substantial Equivalence Information:

1. Predicate device name(s):
Elecsys C-Peptide CalCheck

2. Predicate K number(s):
k040157

{2}

3

3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Characteristic | Predicate device Elecsys C-Peptide CalCheck | Elecsys Anti-TSHR CalCheck  |
|  Intended Use | For use in the verification of the calibration established by the Elecsys C-Peptide reagent on the indicated Elecsys and **cobas e** immunoassay analyzers. | For use in the verification of the calibration established by the Elecsys Anti-TSHR reagent on the indicated Elecsys and **cobas e** immunoassay analyzers.  |
|  Levels | Three | Same  |
|  Format | Lyophilized | Same  |
|  Handling | Reconstitute with exactly 1.0 mL distilled or deionized water and allow standing closed for 15 minutes, then mixing gently. | Same  |
|  Differences  |   |   |
| --- | --- | --- |
|  Feature | Predicate | New Device  |
|  Stability | **Unopened:**
• Store at 2-8°C until expiration date
**Reconstituted:**
• 20 – 25 °C : 4 hrs | **Unopened:**
• Store at 2-8°C until expiration date
**Reconstituted:**
• 15 - 25 °C : 5 hrs  |
|  Matrix | equine serum matrix | Human serum matrix  |

K. Standard/Guidance Document Referenced (if applicable):

None referenced.

L. Test Principle:

Not applicable

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Not applicable

{3}

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: Standardized against NIBSC 1st IS 90/672 Standard

Value Assignment: Values are assigned using a minimum of three Elecsys 2010 / cobas e 411 and three MODULAR ANALYTICS E170 / cobas e 601 Immunoassay Analyzers. Six independent series of analyses are performed on each instrument platform. The target value is calculated as the median of the determined values. Approximate target values are found in the following table. Lot-specific target values may differ slightly after value assignment.

|  Anti-TSHR CalCheck Level | Anti-TSHR Target Values (IU/L)  |
| --- | --- |
|  Check 1 (low) | < 1.0  |
|  Check 2 (medium) | 10  |
|  Check 3 (high) | 38  |

Stability: Stability testing protocols and acceptance criteria were described and found to be acceptable. The CalCheck is stable until the expiration date printed on the vial when stored unopened at 2 – 8°C. Reconstituted vials are stable for five hours at 15 – 25°C.

d. Detection limit:

Not applicable

e. Analytical specificity:

Not applicable

f. Assay cut-off:

Not applicable

{4}

2. Comparison studies:
a. Method comparison with predicate device:
Not applicable
b. Matrix comparison:
Not applicable

3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

5

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K080643](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K080643)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com